{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.6","upperLimit":"56.3","value":"48.9"}]}],"title":"Week 96 response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.6","upperLimit":"54.2","value":"46.8"}]}],"title":"Week 144 response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.5","upperLimit":"52.1","value":"44.7"}]}],"title":"Week 192 response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.5","upperLimit":"48.9","value":"41.6"}]}],"title":"Week 264 response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.5","upperLimit":"45.7","value":"38.4"}]}],"title":"Week 312 (Year 6) response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.5","upperLimit":"44.7","value":"37.4"}]}],"title":"Week 360 (Year 7) response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.5","upperLimit":"42.5","value":"35.3"}]}],"title":"Week 408 (year 8) response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.5","upperLimit":"41.4","value":"34.2"}]}],"title":"Week 468 (year 9) response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.7","upperLimit":"33.7","value":"26.8"}]}],"title":"Week 528 (year 10) response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"}],"units":"Participants"}],"description":"This outcome measure was the percentage of participants in major molecular response (MMR) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase. Participants who required re-initiation of treatment at any time prior to the respective assessment were considered non-responders.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who completed the nilotinib treatment consolidation (NTCS) phase and maintained major molecular response entered the treatment-free remission (TFR) phase. During the TFR phase, nilotinib treatment was discontinued and participants were monitored regularly for molecular response.","id":"OG000","title":"TFR Phase"}],"paramType":"NUMBER","populationDescription":"The full analysis set (FAS) included all participants who completed 52 weeks of nilotinib treatment in the NTCS phase and subsequently entered the TFR phase","reportingStatus":"POSTED","timeFrame":"Weeks 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10","title":"Percentage of Participants in Major Molecular Response (MMR) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase","type":"SECONDARY","unitOfMeasure":"percentage of participants"}